Abstract | IMPORTANCE OF THE FIELD: AREAS COVERED IN THIS REVIEW: The aim of this article is to provide a summative review of the vast amount of clinical trial data now available on these agents. WHAT THE READER WILL GAIN: To locate clinical trials for review, a literature search was performed using PubMed between the dates of 25 May and 30 June 2009. Search parameters were set to isolate only human randomized controlled trials (RCTs) published between 1990 and 2009. Keywords consistently used for each search include: cannabinoids, marijuana, THC, nabilone and dronabinol. Preferential selection was given to the best-designed trials, focusing on placebo-controlled, double-blind RCTs with the largest patient populations, if available. TAKE HOME MESSAGE: As efficacy and tolerability of these agents remain questionable, it is important that cannabinoids not be considered 'first-line' therapies for conditions for which there are more supported and better-tolerated agents. Instead, these agents could be considered in a situation of treatment failure with standard therapies or as adjunctive agents where appropriate.
|
Authors | Dana Turcotte, Josée-Anne Le Dorze, Farid Esfahani, Emma Frost, Andrew Gomori, Mike Namaka |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 11
Issue 1
Pg. 17-31
(Jan 2010)
ISSN: 1744-7666 [Electronic] England |
PMID | 20001426
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Cannabinoids
- nabilone
- Dronabinol
|
Topics |
- Activities of Daily Living
- Cannabinoids
(therapeutic use)
- Cannabis
(adverse effects, chemistry)
- Combined Modality Therapy
(methods)
- Double-Blind Method
- Dronabinol
(analogs & derivatives, pharmacology, therapeutic use)
- Humans
- Hypersensitivity
- Pain
(drug therapy)
- Pain Measurement
(methods)
|